Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.40 |
| ▸ | HTR3B | O95264 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15140350 | 0.84 | TRPV4 (0.46) | TRPV4MEN1KMT2AALDH1A1HTR3E | |
| SCHEMBL30571306 | 0.84 | TRPV4 (0.46) | TRPV4MEN1KMT2AALDH1A1HTR3E | |
| SCHEMBL2496399 | 0.78 | ACHE (0.56) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3016274 | 0.78 | CA12 (0.56) | MEN1KMT2AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL636066 | 0.76 | NFE2L2 (0.42) | SMN1; SMN2KDM4EHTT | |
| SCHEMBL2127233 | 0.73 | TRPV4 (0.55) | TRPV4MEN1KMT2AALDH1A1HTR3E | |
| SCHEMBL29636402 | 0.73 | TRPV4 (0.55) | TRPV4MEN1KMT2AALDH1A1HTR3E | |
| SCHEMBL929274 | 0.72 | ALDH1A1 (0.52) | TRPV4MEN1KMT2AALDH1A1HTR3E | |
| SCHEMBL14808687 | 0.72 | CYP3A4 (0.46) | ALDH1A1LMNASMN1; SMN2KDM4EPOLB | |
| SCHEMBL29958505 | 0.72 | ALDH1A1 (0.52) | TRPV4MEN1KMT2AALDH1A1HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383839-B1 | PROCESS FOR THE PREPARATION OF N,N´-UNSUBSTITUTED CARBOXAMIDINES | ALZCHEM TROSTBERG GMBH (DE) | 2020-05-06 | — | — | EP | disclosed |
| EP-3383839-A2 | PROCESS FOR THE PREPARATION OF N,N´-UNSUBSTITUTED CARBOXAMIDINES | AlzChem Trostberg GmbH (DE) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093495-A2 | PROCESS FOR THE PREPARATION OF N,N´-UNSUBSTITUTED CARBOXAMIDINES | ALZCHEM AG (DE) | 2017-06-08 | — | — | WO | disclosed |
| US-7528124-B2 | 1,3-dihydro-2H-indol-2-one derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20060276449-A1 | 1,3-Dihydro-2h-indol-2-one derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1659121-A1 | 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| EP-1011677-A4 | 4-ARYL-3-AMINOQUINOLINE-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-1011677-A1 | 4-ARYL-3-AMINOQUINOLINE-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | Bristol-Myers Squibb Company (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999009983-A1 | 4-ARYL-3-AMINOQUINOLINE-2-ONE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276449-A1 | 1,3-Dihydro-2h-indol-2-one derivative | AVPR1B, AVPR2, AVPR1A | TRPV4 264/4885MEN1 353/4885KMT2A 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.